Our first clinical candidate, CEL383, is a potential first-in-class anti-TREM1 antibody program for inflammatory bowel disease (IBD). Leveraging our SCOPE platform, we were able to identify a myeloid target with a central role in IBD through our analysis of human tissue samples from patients with ulcerative colitis and Crohn’s disease. Identifying and extensively characterizing subsets of pathogenic cell types that drive resistance to anti-TNF therapy defined a series of targets modulating behavior of these cell subtypes. TREM1 is the first of these targets, an amplifier of mucosal inflammation that resides at the intersection of the microbiome and the immune system.

We plan to file an investigational new drug application for CEL383 with the U.S. Food and Drug Administration within the next year, with a Phase 1 study expected to commence in the first half of 2023.

Celsius is validating multiple novel drug targets for inflammatory bowel disease that were identified through the analysis of hundreds of samples from patients with ulcerative colitis and Crohn’s disease using our SCOPE platform.

Celsius has two antibody drug discovery programs, “Lassen” and “Ledenika,” in immuno-oncology, both directed towards myeloid targets identified through analysis of hundreds of solid tumor samples from patients via the company’s SCOPE platform. We plan to disclose further details on these programs in 2022.

Celsius has two antibody drug discovery programs, “Lassen” and “Ledenika,” in immuno-oncology, both directed towards myeloid targets identified through analysis of hundreds of solid tumor samples from patients via the company’s SCOPE platform. We plan to disclose further details on these programs in 2022.

Through our collaboration with Servier, we are identifying and validating multiple novel targets in colorectal cancer.

Celsius is validating multiple novel drug targets on tumor and immune cells that were identified through the analysis of hundreds of solid tumor samples using our SCOPE platform.